医学研究与教育 ›› 2015, Vol. 32 ›› Issue (1): 36-39.DOI: 10.3969/j.issn.1674-490X.2015.01.008

• 临床研究 • 上一篇    下一篇

丁苯酞联合尼莫地平对血管性痴呆的疗效观察

孙菊平1,代瑞廷2,徐金娥3,安迪1   

  1. 1. 河北大学研究生院,河北 保定 071000;2. 河北大学附属医院神经内科,河北 保定 071000;3. 涞源县中医院,河北 保定 074300
  • 出版日期:2015-02-25 发布日期:2015-02-25
  • 通讯作者: 代瑞廷(1965—),男,河北石家庄人,教授,硕士生导师,主要从事神经心理研究。E-mail: 812873151@qq.com
  • 作者简介:孙菊平(1987—),女,河北邯郸人,在读硕士,主要从事神经心理研究。

Observation of the efficacy of butyiphthalide and nimodipine in the treatment of vascular dementia

SUN Juping1, DAI Ruiting2, XU Jine3, AN Di1   

  1. 1. Postgraduate College of Hebei University, Baoding 071000, China; 2. Neurology Department, Affliated Hospital of Hebei University, Baoding 071000, China; 3. Chinese Medicine Hosipital of Laiyuan County, Baoding 071000, China
  • Online:2015-02-25 Published:2015-02-25

摘要: 目的 观察丁苯酞联合尼莫地平对血管性痴呆的疗效及安全性。方法 将 90 例血管性痴呆患者随机分为 3 组,在常规治疗的基础上,A 组给予丁苯酞及尼莫地平口服,B 组给予丁苯酞口服,C 组给予尼莫地平口服,分别于治疗前和治疗 12 周后对患者进行蒙特利尔认知评估量表(MoCA)、日常生活能力量表(ADL)评分,比较各组治疗效果。记录治疗过程中的不良事件。结果 3 组治疗后 MoCA、ADL 评分均优于治疗前,且差异有统计学意义(P<0.05)。对血管性痴呆患者 MoCA 评分的改善,A 组明显优于 C 组,差异有统计学意义(P<0.05);对血管性痴呆患者 ADL 评分的改善,A、B 组明显优于C 组,差异有统计学意义(P<0.05),A、B 组差异无统计学意义(P>0.05)。3 组不良反应发生率比较无统计学意义(P>0.05)。结论 对血管性痴呆患者认知功能的改善,联合使用丁苯酞及尼莫地平优于单一用药;对血管性痴呆患者生活能力的改善,联合用药及单用丁苯酞效果均优于单用尼莫地平。3 组用药安全性良好。

关键词: 血管性痴呆, 丁苯酞, 尼莫地平, 疗效, 安全性

Abstract: Objective To observe the efficacy and safety of butyiphthalide and nimodipine in the treatment of vascular dementia(VD). Methods Ninety cases with VD were randomly divided into group A(30 cases), group B(30 cases), and group C (30 cases). On the basis of conventional treatment, patients of group A were given 0.2 g butyiphthalide and 30 mg nimodipine for three times a day, group B were given 0.2 g butyiphthalide for three times a day, and group C were given 30 mg nimodipine for three times a day. All the patients were assessed with Montreal cognitive assessment scale (MoCA) and Activities of Daily Living (ADL) for comparison. The adverse events were recorded in the process of treatment. Results The MoCA and ADL Scores of three groups after treatment were better than scores before treatment, the differences were statistically signifucant (P<0.05). Group A could prominently improve the cognitive function of patients with VD, better than group C, the differences were statistically signifucant (P<0.05). Group A and B could prominently improve the cognitive function of patients with VD, better than group C, thedifferences were statistically signifucant (P<0.05). There was no statistically significant difference between A and B group (P>0.05). There were no significant differences in incidence rate of side effect among these groups. Conclusion Butyiphthalide and nimodipine can prominently improve the cognitive function of patients with vascular dementia and better than butyiphthalide or nimodipine alone. Combination therapy and given butyiphthalide alone can prominently improve the ability of daily living of patients with VD, which are better than nimodipine alone. Morever, their securities are good.

Key words: Vascular Dementia, Butyiphthalide, Nimodipine, efficacy, security

中图分类号: